Furthermore, if pharmacologically induced hypoglycaemia is more dangerous to patients with Type 2 diabetes than previously recognized, this would of course only be relevant to treatment with the potential of inducing hypoglycaemia, i.e. sulphonylureas, meglitinides and insulin. Here, INS is linked to type 2 diabetes mellitus.